BONEH BBS-Bioactive Bone Substitutes Oyj

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

This Company announcement contains information on the following management transactions:

  • Subscription of shares with warrants (TO1) 5 December 2022
  • Subscription of shares with warrants (TO2) 29 May 2023
  • Subscription of shares in share issue on 26 June 2023
  • Received shares without consideration on 11 July 2023 (directed share issue without consideration, release 7 June 2023)

____________________________________________

Person subject to the notification requirement

Name: Jalovaara Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20230803191449_6

____________________________________________

Transaction date: 2022-12-05

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 1,925 Unit price: 0.92 EUR

Aggregated transactions

(1): Volume: 1,925 Volume weighted average price: 0.92 EUR

____________________________________________

Transaction date: 2023-05-29

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 1,925 Unit price: 0.65 EUR

Aggregated transactions

(1): Volume: 1,925 Volume weighted average price: 0.65 EUR

____________________________________________

Transaction date: 2023-06-26

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 7,200 Unit price: 0.5 EUR

(2): Volume: 4,020 Unit price: 0.5 EUR

Aggregated transactions

(2): Volume: 11,220 Volume weighted average price: 0.5 EUR

____________________________________________

Transaction date: 2023-07-11

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: OTHER

Description: Received shares without consideration on 11 July 2023 (directed share issue without consideration, release 7 June 2023)

Transaction details

(1): Volume: 385 Unit price: 0.00 EUR

Aggregated transactions

(1): Volume: 385 Volume weighted average price: 0.00 EUR

____________________________________________

Contact information:

Ilkka Kangasniemi, CEO

040 708 0307



EN
07/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BBS-Bioactive Bone Substitutes Oyj

 PRESS RELEASE

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. BBS is currently in the process of searching for a new in-house CFO. The appoi...

 PRESS RELEASE

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä BBS-Bioactive Bone Substitutes Oyj, yhtiötiedote, 6.3.2024 klo 11:15 Muutos BBS-Bioactive Bone Substitues Oyj:n johtoryhmässä Oy JAMERCO Ltd. on tänään irtisanonut palvelusopimuksen BBS-Bioactive Bone Substitutes Oyj:n (BBS) kanssa, minkä seurauksena Jari Kortesluoman tehtävä BBS:n talousjohtajana ja johtoryhmän jäsenenä päättyy. Jari Kortesluoma jatkaa BBS:n talousjohtajan tehtävien hoitamista kahden kuukauden irtisanomisajan puitteissa. BBS hakee uutta työsuhteista talouspäällikköä ja nimityksestä tiedotetaa...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023...

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited) BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at . Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTS In the secon...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallis...

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallisen vaiheen valmistelut alkaneet (tilintarkastamaton) BBS-Bioactive Bone Substitutes Oyj, Tilinpäätöstiedote, 26.2.2024 klo 17.45 Tämä tiedote on tiivistelmä BBS-Bioactive Bone Substitutes Oyj:n tilinpäätöstiedotteesta tammi–joulukuu 2023. Koko raportti on tämän yhtiötiedotteen liitteenä pdf-tiedostona. Raportti on saatavilla myös BBS-Bioactive Bone Substitutes Oyj:n verkkosivuilla osoitteessa. Kaupallisen vaiheen valmistelut alkaneet HEINÄ-JOULUKUU Vuoden 2023 toisella puoliskolla BBS eteni merkittävästi ensimmäisen ...

 PRESS RELEASE

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of a...

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch